Trial Profile
A Phase I Study of Avelumab in Combination With Decitabine as First Line Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 10 Dec 2019 Results assessing safety of avelumab in combination with decitabine as a first-line treatment of unfit patients, presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 19 Aug 2019 Status changed from recruiting to discontinued.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.